Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 14, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$17.3B
sum of reported positions
Reported positions
354
Changes vs prior quarter
395
84 new · 85 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 396 measured positions in 8 quarters, the typical new or larger position finished −3.9 pts against the S&P 500 and 42% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
| Company | Shares | Value | Weight |
|---|---|---|---|
| 985K | $470M | 2.7% | |
| 6.85M | $322M | 1.9% | |
| 959K | $321M | 1.9% | |
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $13.6B | $17.3B |
| Positions | 355 | 354 |
| Biggest line | — | Taiwan Semiconductor Manufacturing 3% |
| 4.42M |
| $267M |
| 1.5% |
| 786K | $262M | 1.5% |
| 2.8M | $249M | 1.4% |
Crinetics Pharmaceuticals Inc | 6.46M | $242M | 1.4% |
Apogee Therapeutics Inc | 1.74M | $231M | 1.3% |
| 1.53M | $230M | 1.3% |
| 6.72M | $223M | 1.3% |
| 557K | $217M | 1.3% |
| 4.73M | $192M | 1.1% |
| 497K | $189M | 1.1% |
| 1.31M | $187M | 1.1% |
| 229K | $174M | 1.0% |
| 1.77M | $171M | 1.0% |
| 6.16M | $152M | 0.9% |
| 4.43M | $148M | 0.9% |
| 1.21M | $144M | 0.8% |
| 1.56M | $142M | 0.8% |
| 517K | $141M | 0.8% |
| 227K | $140M | 0.8% |
| 4.83M | $140M | 0.8% |
| 1.99M | $138M | 0.8% |
| 355K | $134M | 0.8% |
Symbotic (SYM)
258K shares
Bbb Foods (TBBB)
170K → 265K shares (+56%)
Climb Bio (CLYM)
601K → 790K shares (+32%)
Beone Medicines (ONC)
155K → 36K shares (−77%)
Fabrinet (FN)
391K → 18K shares (−95%)
Gold Fields (GFI)
296K → 301K shares (+2%)
Larimar Therapeutics (LRMR)
2.93M → 3.16M shares (+8%)
Citi Trends (CTRN)
163K shares
Cue Biopharma (CUE)
292K shares
Gorilla Technology Group (GRRR)
462K shares
Sprott (SII)
83K → 81K shares (−3%)
Pursuit Attractions & Hospitality, Inc. (PRSU)
143K shares
Monopar Therapeutics (MNPR)
33K → 84K shares (+154%)
Precision Biosciences (DTIL)
995K → 947K shares (−5%)
Amer Sports (AS)
207K → 213K shares (+3%)
Spire Global (SPIR)
370K shares
Tss (TSSI)
536K shares
Shoulder Innovations (SI)
254K shares
Kardigan (KARD)
200K shares
Neurogene (NGNE)
33K → 144K shares (+338%)
Intrepid Potash (IPI)
314K → 130K shares (−59%)
Invivyd (IVVD)
8.44M → 4.81M shares (−43%)
Assembly Biosciences (ASMB)
150K shares
Alphabet (GOOGL)
12K → 10K shares (−12%)
Pampa Energy (PAM)
21K → 43K shares (+103%)
